Oral JAK Inhibitors Resulted in Hair Regrowth for Patients With Alopecia Areata
Investigators aimed to assess the efficacy and safety of JAK inhibitors for the treatment of alopecia areata.
Investigators aimed to assess the efficacy and safety of JAK inhibitors for the treatment of alopecia areata.
We speak with prominent alopecia researchers and experts to gain insights into the burden associated with hair loss as well as standard and new treatment options for alopecia.
Researchers sought to investigate the reliability and characteristic content of the most viewed alopecia-related videos on TikTok focusing on diagnoses, content type, and content creators.
CTP-543 is an investigational oral selective inhibitor of JAK1 and JAK2.
Patients with frontal fibrosing alopecia (FFA) do not need to have vitamin D levels tested as deficiency is unlikely tied to the pathogenesis of FFA.
The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata.
Literature on clinical studies and reports investigating the association between new-onset alopecia areata or the exacerbation of preexisting alopecia areata following infection with SARS-CoV-2 are reviewed.
The efficacy of ritlecitinib in treating patients with alopecia areata is assessed.
The efficacy of various doses of minoxidil, dutasteride, and finateride for the treatment of male androgenic alopecia (AGA) is evaluated.
Disparities in dermatology and the role of ethnic skin centers in addressing these issues are discussed with Angela Lamb, MD.